FDA award Clovis’ prostate cancer treatment Breakthrough Therapy status
Clovis Oncology’s Rucaparib has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials achieves favourable results. The FDA has said that phase 2 data suggest the drug could represent a new therapy option for men whose cancer has progressed despite chemotherapy, and